The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

1259 ET - Moderna's finding that the mRNA-based vaccine it made with Merck successfully prevented cancer from spreading or returning in melanoma patients is "a big de-risking event for its personalized therapy approach," Wolfe Research analysts write in a note, upgrading the stock to peer perform from underperform. The market's ebullient response may suggest that some traders misunderstood the vaccine as a preventative treatment, they write, and Moderna may still not reach profitability until 2030. Still, the recent data, as well as Moderna's cost-cutting efforts and its patent litigation settlement with Arbutus Biopharma and Genevant Sciences GmbH, lead to a balanced risk/reward at the stock's current levels, the analysts write. Moderna's stock gains 14% to $158.10 and has nearly tripled in value over the past month. (elias.schisgall@wsj.com)

0833 ET - Novo Nordisk's sales growth could be flat this year, J.P. Morgan says. The Danish drugmaker recently raised its guidance and now forecasts sales growth ranging from flat to minus 6%. The bank raises its 2026 sales forecasts by 5%, largely due to higher forecasts for diabetes and weight-loss drugs Ozempic and Wegovy, partially offset by slowing launch momentum of oral Wegovy in the U.S. Novo Nordisk's top-line could still see modest 1% growth in 2027, JPM says. The bank expects 2% sales growth in 2028, with any further acceleration largely dependent on the successful development of zenagamtide, particularly in the oral format, which could have the highest weight loss of any of the oral drugs. JPM retains its neutral rating for the stock and lifts its price target to 275 Danish kroner from 250 kroner. Shares rise 2.2% to 305.80 kroner. (dominic.chopping@wsj.com)

1811 ET [Dow Jones]--Insmed's shares aren't being given a fair shake by traders, who may be using their positions as "a source of funds" given a broader run-up in biotechnology stocks, Mizuho analysts write in a note. They raise their price target to $195 from $192, citing the Japanese approval of the company's Brinsupri treatment for non-cystic fibrosis bronchiectasis. Investors are likely overlooking the significance of the Japanese launch, they write, adding that the company has strong business fundamentals and an ability to execute. "We continue to see INSM shares undervalued," the analysts write. Shares of Insmed close down 1.4% at $123.98, having fallen 29% this year.